CSPC Pharmaceutical Group Limited (HKG:1093)
Hong Kong · Delayed Price · Currency is HKD 8.55
+0.18 (2.15%)
Jul 24, 2026, 4:08 PM HKT
CSPC Pharmaceutical Group Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 25,457 | 26,006 | 29,009 | 31,450 | 30,937 | 27,867 |
Revenue Growth | -5.86% | -10.35% | -7.76% | 1.66% | 11.02% | 11.73% |
Gross Profit Gross Profit Growth | 16,622 | 17,059 | 20,299 | 22,177 | 22,256 | 21,135 |
Operating Income Operating Income Growth | 3,421 | 3,961 | 5,366 | 7,016 | 6,760 | 6,249 |
Net Income Net Income Growth | 3,264 | 3,882 | 4,328 | 5,873 | 6,091 | 5,605 |
Earnings Per Share EPS Growth | 0.29 | 0.34 | 0.37 | 0.49 | 0.51 | 0.47 |
EPS Growth | -20.63% | -7.84% | -25.47% | -3.21% | 9.00% | 8.64% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Nervous System Nervous System Growth | 7,817 | 7,817 | 9,645 | 9,089 | 8,108 | 7,544 |
Oncology Oncology Growth | 2,201 | 2,201 | 4,400 | 6,139 | 7,340 | 7,711 |
Anti-Infectives Anti-Infectives Growth | 3,324 | 3,324 | 4,086 | 4,236 | 3,540 | 2,949 |
Cardiovascular Cardiovascular Growth | 1,834 | 1,834 | 2,079 | 2,440 | 2,889 | 2,765 |
Respiratory System Respiratory System Growth | 1,223 | 1,223 | 1,199 | 1,560 | 696 | 402 |
Digestion and Metabolism Digestion and Metabolism Growth | 943.33 | 943.33 | 1,051 | 889 | 755 | 497 |
Other Therapeutic Areas Other Therapeutic Areas Growth | 1,453 | 1,453 | 1,258 | 1,249 | 1,006 | 764 |
Vitamin C Vitamin C Growth | 2,231 | 2,231 | 1,994 | 1,929 | 2,529 | 2,149 |
Antibiotics Antibiotics Growth | 1,426 | 1,426 | 1,589 | 1,712 | 1,503 | 1,670 |
License Fee Income License Fee Income Growth | 1,789 | 1,789 | 17.83 | 34.7 | 185.82 | 48.53 |
Functional Food and Others Functional Food and Others Growth | 1,765 | 1,765 | 1,690 | 2,172 | 2,385 | 1,366 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 10,373 | 10,373 | 9,137 | 13,765 | 14,566 | 11,307 |
Total Debt Total Debt Growth | 641.11 | 641.11 | 507.33 | 706.9 | 582.54 | 94.04 |
Net Cash (Debt) Net Cash Growth | 9,732 | 9,732 | 8,630 | 13,058 | 13,984 | 11,213 |
Net Cash Growth | 12.77% | 12.77% | -33.91% | -6.62% | 24.70% | 24.61% |
Net Cash Per Share Net Cash Per Share Growth | 0.85 | 0.85 | 0.74 | 1.10 | 1.17 | 0.94 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | - | 5,832 | 4,535 | 4,179 | 7,627 | 4,637 |
Capital Expenditures CapEx Growth | - | -1,959 | -2,015 | -1,624 | -2,220 | -1,410 |
Free Cash Flow Free Cash Flow Growth | - | 3,872 | 2,519 | 2,555 | 5,407 | 3,226 |
Free Cash Flow Growth | - | 53.70% | -1.40% | -52.74% | 67.58% | -40.07% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 65.29% | 65.59% | 69.97% | 70.51% | 71.94% | 75.84% |
Operating Margin | 13.44% | 15.23% | 18.50% | 22.31% | 21.85% | 22.43% |
Pretax Margin | 16.29% | 18.49% | 19.23% | 23.50% | 24.51% | 24.57% |
Profit Margin | 12.82% | 14.93% | 14.92% | 18.68% | 19.69% | 20.11% |
FCF Margin | - | 14.89% | 8.69% | 8.12% | 17.48% | 11.58% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.290 | 0.261 | 0.238 | 0.258 | 0.191 | 0.152 |
Dividend Per Share Growth | 11.54% | 9.50% | -7.75% | 35.08% | 25.66% | 41.58% |
Dividend Yield | 3.39% | 3.52% | 5.57% | 4.32% | 3.02% | 2.59% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 26, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 26.30 | 22.31 | 11.98 | 13.30 | 14.19 | 14.67 |
Forward PE | 12.36 | 17.08 | 9.76 | 12.05 | 13.86 | 15.70 |
P/FCF Ratio | - | 22.37 | 20.58 | 30.56 | 15.99 | 25.49 |
PS Ratio | 3.38 | 3.33 | 1.79 | 2.48 | 2.79 | 2.95 |